Chargement en cours...
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1(mut)), present in 7–14% of AML patients, have been discovered recently, opening the door to targeted agents aiming to...
Enregistré dans:
| Publié dans: | Blood Lymphat Cancer |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6663038/ https://ncbi.nlm.nih.gov/pubmed/31413655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S177913 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|